

# Biopharmaceutical Contract Fill-and-Finish: Best Practices Study 2015

## TABLE OF CONTENTS

---

<b>Chapter 1:</b>	<b>EXECUTIVE SUMMARY</b>	
	<b>1.1 Introduction</b>	<b>1-1</b>
	<b>1.2 Market Overview</b>	<b>1-2</b>
	1.2.1 Introduction	1-2
	1.2.2 Industry Drivers	1-3
	1.2.3 Market Size	1-5
	<b>1.3 Summary of Customer Needs</b>	<b>1-6</b>
	1.3.1 Products	1-6
	1.3.2 Outsourcing Strategies	1-8
	1.3.3 Outsourcing Budgets	1-9
	<b>1.4 Summary of Fill-and-Finish Contractors' Capabilities</b>	<b>1-10</b>
	1.4.1 Dosage Forms	1-11
	1.4.2 Capacity Increases	1-12
	1.4.3 Industry and Company Growth Rates	1-13
	1.4.4 Contracting Business by Product Type	1-14
	<b>1.5 Industry Trends and Observations</b>	<b>1-15</b>
<b>Chapter 2:</b>	<b>METHODOLOGY, DEFINITIONS, AND ACRONYMS</b>	
	<b>2.1 Research Objectives</b>	<b>2-1</b>
	<b>2.2 Research Methodology</b>	<b>2-2</b>
	<b>2.3 Definition of Parenteral Fill-and-Finish Manufacturing</b>	<b>2-4</b>
	<b>2.4 Box-and-Whiskers Plot Definition</b>	<b>2-4</b>
	<b>2.5 Acronyms</b>	<b>2-5</b>
<b>Chapter 3:</b>	<b>FILL-AND-FINISH CONTRACT MANUFACTURING: MARKET OVERVIEW</b>	
	<b>3.1 Introduction</b>	<b>3-1</b>
	<b>3.2 Suppliers: The Fill-and-Finish Contract Manufacturers</b>	<b>3-2</b>
	3.2.1 Types of Fill-and-Finish Contract Companies	3-2
	3.2.2 Fill-and-Finish Contract Manufacturing Companies	3-3
	3.2.3 Dosage Forms and Services	3-5
	3.2.4 Fill-and-Finish Contract Manufacturing Organizations' Capacities	3-7

# Biopharmaceutical Contract Fill-and-Finish: Best Practices Study 2015

## TABLE OF CONTENTS (continued)

---

<b>Chapter 3:</b>	<b>3.3 The Customers: Pharmaceutical and Biotechnology Companies</b>	<b>3-9</b>
	3.3.1 <i>Customers' Products</i>	3-9
	3.3.2 <i>Outsourced Fill-and-Finish by Dosage Form</i>	3-10
	3.3.3 <i>Customers' Future Outsourcing Expectations</i>	3-11
	3.3.4 <i>Outsourcing Needs</i>	3-12
	<b>3.4 Market Capacity</b>	<b>3-14</b>
	<b>3.5 Market Size</b>	<b>3-15</b>
	3.5.1 <i>Estimates of Market Size Based on Customer Spending</i>	3-15
	3.5.2 <i>Estimates of Market Size Based on Contractor Revenues</i>	3-17
	3.5.3 <i>Market Size by Dosage Form and Service Categories</i>	3-17
	<b>3.6 Market Growth Forecasts</b>	<b>3-18</b>
	<b>3.7 Trends in the Fill-and-Finish Contract Manufacturing Market</b>	<b>3-20</b>
	3.7.1 <i>Industry Opportunities and Challenges</i>	3-20
	3.7.2 <i>Overall Industry Trends</i>	3-21
<hr/>		
<b>Chapter 4:</b>	<b>PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES: CLIENT ANALYSIS</b>	
	<b>4.1 Introduction</b>	<b>4-1</b>
	4.1.1 <i>Respondent Titles and Location</i>	4-1
	4.1.2 <i>In-House Manufacturing Sites</i>	4-2
	4.1.3 <i>Recombinant Large-Molecule Drug Products on Market</i>	4-4
	<b>4.2 Manufacturing Demand</b>	<b>4-5</b>
	4.2.1 <i>Manufacturing Needs</i>	4-5
	4.2.2 <i>Dosage Forms</i>	4-11
	4.2.3 <i>Clinical and Commercial Products</i>	4-13
	<b>4.3 Manufacturing Technologies</b>	<b>4-17</b>
	4.3.1 <i>Planned Format for Drug Launch</i>	4-17
	4.3.2 <i>New Delivery Technologies</i>	4-19
	4.3.3 <i>Special Handling Requirements</i>	4-23
	4.3.4 <i>Yield Loss</i>	4-27

# Biopharmaceutical Contract Fill-and-Finish: Best Practices Study 2015

## TABLE OF CONTENTS (continued)

---

<b>Chapter 4:</b>	<b>4.4 Outsourcing Strategies</b>	<b>4-32</b>
	4.4.1 <i>Current In-House Filling Capacity and Outsourcing Strategy</i>	4-32
	4.4.2 <i>Changes to In-House Filling Capacity</i>	4-38
	4.4.3 <i>Impact of Core/Non-Core Technology</i>	4-41
	4.4.4 <i>Impact of Standard/Non-Standard Technology</i>	4-45
	4.4.5 <i>Focus of Filling Outsourcing over Next 5 Years</i>	4-48
	<b>4.5 Outsourcing Needs</b>	<b>4-52</b>
	4.5.1 <i>Outsourced Services</i>	4-52
	4.5.2 <i>Areas Underserved by Fill-and-Finish CMOs</i>	4-54
	4.5.3 <i>Key Challenges a Fill-and-Finish CMO Can Help Alleviate</i>	4-60
	<b>4.6 Contractor Selection</b>	<b>4-65</b>
	4.6.1 <i>Essential Characteristics Sought in a F&amp;F Contractor</i>	4-65
	4.6.2 <i>Key Components for Successful Collaboration with a Fill-and-Finish CMO</i>	4-72
	4.6.3 <i>Regional Outsourcing Preference</i>	4-76
	4.6.4 <i>Opinion of Emerging Market CMOs</i>	4-79
	<b>4.7 Contractor Pricing</b>	<b>4-84</b>
	4.7.1 <i>Price Models Used</i>	4-84
	4.7.2 <i>Fee Structure: Technology Transfer</i>	4-88
	4.7.3 <i>Fee Structure: Reservation</i>	4-92
	4.7.4 <i>Fee Structure: Cancellation</i>	4-95
	<b>4.8 Outsourced Spending</b>	<b>4-100</b>
	4.8.1 <i>Prices Paid to Fill-and-Finish CMOs</i>	4-100
	4.8.2 <i>Outsourcing Budgets</i>	4-105
	4.8.3 <i>Outsourcing Budgets by Service Category</i>	4-108
	<b>4.9 Contractor Relationships</b>	<b>4-112</b>
	4.9.1 <i>Identifying Contract Partners</i>	4-112
	4.9.2 <i>Preferred Contractors</i>	4-114
	4.9.3 <i>Top Concerns of Contractors Meeting Expectations</i>	4-116
	4.9.4 <i>Warranties, Guarantees and Indemnifications</i>	4-120
	4.9.5 <i>Ideal Production Network or Alliance Structure</i>	4-123
	<b>4.10 Future Trends and Expectations</b>	<b>4-129</b>
	4.10.1 <i>Regulatory Requirement Challenges</i>	4-129
	4.10.2 <i>Future F&amp;F Manufacturing Challenges and Bottlenecks</i>	4-132
	4.10.3 <i>Future Technology and Operational Trends</i>	4-137
	4.10.4 <i>Future Trends in Biopharmaceutical Fill-and-Finish Contract Manufacturing</i>	4-145

# Biopharmaceutical Contract Fill-and-Finish: Best Practices Study 2015

## TABLE OF CONTENTS (continued)

---

<b>Chapter 5:</b>	<b>FILL-AND-FINISH CONTRACT MANUFACTURERS</b>	
<b>5.1</b>	<b>Introduction</b>	<b>5-1</b>
5.1.1	<i>Respondents' Titles and Experience</i>	5-1
5.1.2	<i>Company Locations</i>	5-2
5.1.3	<i>Regulatory Approval Status</i>	5-3
5.1.4	<i>One-Stop-Shop CMO Model</i>	5-4
<b>5.2</b>	<b>Capacity</b>	<b>5-8</b>
5.2.1	<i>Dosage Forms</i>	5-8
5.2.2	<i>Current Capacity for Fill-and-Finish</i>	5-10
5.2.3	<i>Current Capacity for Lyophilization</i>	5-13
5.2.4	<i>Capacity Expansions</i>	5-15
<b>5.3</b>	<b>Manufacturing Practices</b>	<b>5-17</b>
5.3.1	<i>Contracting Business by Product Type</i>	5-17
5.3.2	<i>Current and Future Capacity Utilization</i>	5-19
5.3.3	<i>Average Batch Size and Batches per Fill Line</i>	5-21
5.3.4	<i>Number of Employees by Function</i>	5-24
5.3.5	<i>Cost Reduction Plans</i>	5-25
<b>5.4</b>	<b>Manufacturing Technologies</b>	<b>5-28</b>
5.4.1	<i>Technology Impacts on Operations</i>	5-28
5.4.2	<i>Average Yield Loss</i>	5-30
5.4.3	<i>Focus of Capabilities in Next 5 Years</i>	5-32
<b>5.5</b>	<b>Pricing</b>	<b>5-35</b>
5.5.1	<i>Price Structures for Fill-and-Finish</i>	5-35
5.5.2	<i>Batch Pricing</i>	5-38
5.5.3	<i>Contractors' Technology Transfer Fees</i>	5-40
5.5.4	<i>Contractors' Reservation Fees</i>	5-43
5.5.5	<i>Contractors' Cancellation Fees</i>	5-44
5.5.6	<i>Gross Profit Margin</i>	5-46
<b>5.6</b>	<b>Customer Relationships</b>	<b>5-47</b>
5.6.1	<i>Strengths and Weaknesses of Contract Manufacturers</i>	5-47
5.6.2	<i>Competitive Attributes</i>	5-51
5.6.3	<i>Warranties, Guarantees and Indemnifications</i>	5-53
5.6.4	<i>Production Networks or Alliances</i>	5-56
5.6.5	<i>Trade Shows</i>	5-59

# Biopharmaceutical Contract Fill-and-Finish: Best Practices Study 2015

## TABLE OF CONTENTS (continued)

---

<b>Chapter 5:</b>	<b>5.7 Fill-and-Finish Industry Revenues and Growth</b>	<b>5-61</b>
	<i>5.7.1 Opportunities for Growth in the Fill-and-Finish Industry</i>	5-61
	<i>5.7.2 Industry and Company Growth Rates</i>	5-64
	<i>5.7.3 Current and Expected Revenue Categories</i>	5-66
	<i>5.7.4 Revenues from Industry Segments</i>	5-68
	<i>5.7.5 Revenues from World Regions</i>	5-70
	<b>5.8 Challenges and Future Trends for F&amp;F Manufacturing</b>	<b>5-71</b>
	<i>5.8.1 Most Significant Challenges/Threats</i>	5-71
	<i>5.8.2 Regulatory Requirement Challenges</i>	5-74
	<i>5.8.3 Potential Growth Areas</i>	5-76
	<i>5.8.4 Trends for the Future of F&amp;F Contract Manufacturing</i>	5-78

---

**Appendix A:** Write-Ups of Interviews with 26 Pharmaceutical and Biotechnology Company  
BioManufacturing Directors Worldwide, Unnamed and Edited for Confidentiality

**Appendix B:** Directory of Biopharmaceutical Fill-and-Finish Contract Manufacturers

**Appendix C:** Interview Guide for Pharmaceutical and Biotechnology Company  
Respondents

**Appendix D:** Interview Guide for Biopharmaceutical Fill-and-Finish Contract Manufacturers

---

# Biopharmaceutical Contract Fill-and-Finish: Best Practices Study 2015

## LIST OF TABLES

---

### Chapter 1

1.2-1	Biopharmaceutical Fill-and-Finish Contract Manufacturing Industry Capacity Estimate in Units	1-4
1.3-1	Respondents Capacity by Segment	1-8
1.3-2	Outsource Decision Criterion	1-9
1.4-1	Fill Line Expansion Plans	1-13
1.5-1	Industry Trends and Challenges	1-16

### Chapter 2

2.2-1	Market Research Steps	2-2
2.5-1	Acronyms	2-5

### Chapter 3

3.2-1	Rating of Respondents' Fill-and-Finish Contract Manufacturers	3-4
3.2-2	CMO Revenue Mix by Service Category: 2015	3-7
3.2-3	Biopharmaceutical F&F Contract Manufacturing Industry Capacity Estimates in Units	3-8
3.3-1	Estimates of Needs for Outsourced Volumes for the Respondent Group	3-13
3.4-1	Biopharmaceutical F&F Outsourced Manufacturing Capacity Utilization	3-15
3.5-1	Worldwide 2015 Market Size for Biopharmaceutical Fill-and-Finish Contract Manufacturing: Estimates Based on Customer Spending: US\$	3-16
3.5-2	Worldwide 2015 Market Size for Biopharmaceutical Fill-and-Finish Contract Manufacturing: Estimates Based on Contractors' Revenues: US\$	3-17
3.5-3	Market Size by Dosage Forms: US\$	3-17
3.5-4	Market Size by Service Category: US\$	3-18
3.7-1	Observations on Biopharmaceutical Fill-and-Finish Contract Manufacturing Industry Trends: Manufacturing Trends	3-21

### Chapter 4

4.1-1	Titles of Pharmaceutical and Biotechnology Company Respondents	4-2
4.1-2	Location of In-House Fill-and-Finish Manufacturing Sites	4-4
4.1-3	Number of Recombinant Large-Molecule Drug Products on Market	4-4

# Biopharmaceutical Contract Fill-and-Finish: Best Practices Study 2015

## LIST OF TABLES (continued)

---

### Chapter 4

4.2-1	Respondents' Current and Expected Capacity Needs for Outsourced Product – Vials (Lyophilized)	4-6
4.2-2	Respondents' Current and Expected Capacity Needs for Outsourced Product – Vials (Not Lyophilized)	4-7
4.2-3	Respondents' Current and Expected Capacity Needs for Outsourced Products – Syringes (Lyophilized)	4-8
4.2-4	Respondents' Current and Expected Capacity Needs for Outsourced Products – Syringes (Not Lyophilized)	4-9
4.2-5	Respondents' Current and Expected Capacity Needs for Outsourced Products – Cartridge (Not Lyophilized)	4-9
4.2-6	Number of Outsourced Products by Phase by Year	4-12
4.2-7	Average Outsourcing Percentage by Dosage Form	4-13
4.2-8	Number of Biopharmaceutical Products Filled by Dosage Form	4-14
4.2-9	Types of Respondents' Biopharmaceutical Products by Dosage Form	4-17
4.3-1	Delivery Technologies Under Investigation	4-21
4.3-2	Cause for Fill-and-Finish Yield Losses	4-29
4.4-1	Respondent Capacity by Segment	4-33
4.4-2	Outsource Decision Criterion – Respondents with In-House Capacity	4-34
4.4-3	Outsource Decision Criterion – Respondents with No In-House Capacity	4-36
4.4-4	Impact of Core Technology on Outsourcing Decision	4-43
4.4-5	Focus of Fill-and-Finish Outsourcing Efforts in Next 5 Years	4-49
4.5-1	Outsourcing of Fill-and-Finish Related Services	4-53
4.5-2	Number of Products Currently and Planned to Outsource by Service	4-54
4.5-3	Areas Underserved by Fill-and-Finish CMOs	4-55
4.5-4	Challenges Fill-and-Finish CMOs can Help Alleviate	4-61
4.6-1	Ranked Characteristics of a Good Service Level at F&F Contractor	4-66
4.6-2	Rationale for Number '1' Ranked Good Service Characteristic	4-68
4.6-3	Key Component for Successful Collaboration	4-72
4.6-4	Regional Outsourcing Preferences	4-77
4.6-5	Observations and Influences on Opinion about Emerging-Market CMOs	4-80
4.7-1	Price Model Used for Fill-and-Finish Services by Respondent Type	4-84
4.7-2	Average Technology Transfer Fees Paid by Dosage Form	4-89
4.8-1	Price Per-Batch by Dosage Form by Product Phase	4-101
4.8-2	Examples of Other Services and Material Charges	4-105
4.8-3	Fill-and-Finish Outsourcing Budgets by Respondent Type: 2015, 2017, 2020	4-107
4.8-4	Simple Average: Percentage of F&F Outsourcing Budget by Service	4-109
4.8-5	Weighted Average: Percentage of F&F Outsourcing Budget by Service	4-111

# Biopharmaceutical Contract Fill-and-Finish: Best Practices Study 2015

## LIST OF TABLES (continued)

---

### Chapter 4

4.9-1	Search Modes for Fill-and-Finish Contractors	4-113
4.9-2	Rating of Respondents' Fill-and-Finish Contract Manufacturers	4-115
4.9-3	Top Concerns of Fill-and-Finish Contractors Meeting Expectations	4-116
4.9-4	Warranties, Guarantees and Indemnifications Negotiated by Respondents	4-121
4.9-5	Proposed Models and Arrangements with a CMO	4-125
4.10-1	Regulatory Requirements That Present the Greatest Challenges	4-129
4.10-2	Challenges and Bottlenecks Facing Fill-and-Finish Manufacturing	4-133
4.10-3	Technology Trends in Drug Presentations	4-138
4.10-4	Technology Trends at CMOs	4-139
4.10-5	Operational and Business Trends in Fill-and-Finish Contract Manufacturing	4-140
4.10-6	Future Trends in Biopharmaceutical Fill-and-Finish Contract Manufacturing	4-145

### Chapter 5

5.1-1	Titles of Fill-and-Finish Contractor Respondents	5-1
5.1-2	Fill-and-Finish Contractors: Headquarter Locations	5-3
5.1-3	Regulatory Agency Approvals	5-4
5.1-4	Relevance of Being a One-Stop-Shop	5-5
5.2-1	Average Batch Size per Fill Line and Contractor	5-11
5.2-2	Fill Capacity by Batch Size at Respondents' Facilities in 2015	5-11
5.2-3	Lyophilizer Capacity by Shelf Space at Respondents' Facilities in 2015	5-13
5.2-4	Lyophilizer Capacity by Batch Size at Respondents' Facilities in 2015	5-14
5.2-5	Fill Line Expansion Plans	5-16
5.2-6	Lyophilizer Expansion Plans	5-17
5.3-1	Percent of Contracting Business by Product Type: 2015 and 2017	5-18
5.3-2	Capacity Utilization Rate: Fill Line	5-19
5.3-3	Capacity Utilization Rate: Lyophilization	5-21
5.3-4	Number of Batches Ran per Fill Line	5-22
5.3-5	Batch Size Ran by Fill Line	5-23
5.3-6	Number of Employees by Function	5-24
5.3-7	Plans to Reduce Fill-and-Finish Manufacturing Costs	5-26
5.4-1	Technology Impacts on Fill-and-Finish Operations	5-29
5.4-2	Sources of Product Yield Loss	5-31
5.4-3	Focus of Manufacturing Capabilities	5-33
5.5-1	Pricing Methods for Clinical and Commercial Phase	5-37
5.5-2	Calculation Methods of Technology Transfer Fees	5-41
5.5-3	Contractors' Cancellation Fees: Average Percentage of Total Project Fee	5-45
5.5-4	Gross Profit Margin	5-46



# Biopharmaceutical Contract Fill-and-Finish: Best Practices Study 2015

## LIST OF TABLES (continued)

---

### Chapter 5

5.6-1	Contract Manufacturers' Strengths and Weaknesses	5-48
5.6-2	Contractor Competitive Advantage	5-51
5.6-3	Warranties, Guarantees and Indemnifications Accepted by F&F CMOs	5-54
5.6-4	Desired Arrangements with Clients	5-57
5.6-5	Trade Shows Named by Fill-and-Finish Contractors	5-60
5.6-6	Trade Shows for Best Quality Leads	5-60
5.6-7	Trade Shows for Best Technical Information	5-61
5.7-1	Opportunities for Growth in the Fill-and-Finish Industry	5-62
5.7-2	Annual Growth Rates: Industry Estimate versus Company Forecast	5-64
5.7-3	Revenue by Service Category: 2015	5-66
5.7-4	Revenue Change Expected by Service Category: 2015 to 2017	5-68
5.7-5	Customer Mix	5-69
5.7-6	Geographic Mix	5-70
5.8-1	Future Challenges to Business Operations	5-72
5.8.2	Current Regulatory Challenges	5-74
5.8.3	Potential Fill-and-Finish Manufacturing Growth Areas	5-76
5.8.4	Future Technology Trends	5-78
5.8.5	Future Business Trends	5-79

# Biopharmaceutical Contract Fill-and-Finish: Best Practices Study 2015

## LIST OF FIGURES

---

### Chapter 1

1.2-A	Size of Worldwide Biopharmaceutical Fill-and-Finish Contract Manufacturing Industry in US\$B	1-6
1.3-A	Respondents' 82 Biopharmaceutical Products by Phase	1-7
1.3-B	Number of Products Outsourced by Dosage Form: 2015–2020	1-7
1.3-C	Simple Average Percentages of Expected Overall Outsourced Budget	1-10
1.4-A	Dosage Forms Produced by Number of Contractor Respondents	1-11
1.4-B	Percent of Fill Lines Available among Contractor Respondents for Various Dosage Forms	1-12
1.4-C	Annual Growth Rates: Industry Estimate versus Company Forecast	1-14
1.4-D	Percent of Contracting Business by Product Type: 2015 and 2017	1-15

### Chapter 2

2.4-A	Explanation of Box-and-Whiskers Plot	2-5
-------	--------------------------------------	-----

### Chapter 3

3.2-A	Dosage Forms Produced by Number of Contractor Respondents	3-5
3.2-B	Percent of Fill Lines Available among Contractor Respondents for Various Dosage Forms	3-6
3.3-A	Respondents' 82 Biopharmaceutical Products by Phase	3-10
3.3-B	Percent of Products Outsourced: 2015	3-11
3.3-C	Simple Average Percentages of Expected Overall Outsourcing Budget	3-12
3.3-D	Number of Products Outsourced by Dosage Form: 2015–2020	3-13
3.3-E	Estimates of Needs for Outsourced Batches for the Worldwide Industry	3-14
3.6-A	Size of the Worldwide Biopharmaceutical Fill-and-Finish Contract Manufacturing Market in US\$B	3-19

### Chapter 4

4.1-A	In-House Fill-and-Finish Manufacturing Capability	4-3
4.2-A	Summation of Outsourced Units Required – Vials	4-10
4.2-B	Summation of Outsourced Units Required – Syringes	4-11
4.2-C	Percentage of Products Outsourced – 2015	4-12
4.2-D	Number of Respondents' Products Produced by Dosage Form	4-15
4.2-E	Respondents' 82 Biopharmaceutical Products by Phase	4-15
4.2-F	Respondents' 82 Biopharmaceutical Products by Company Type	4-16
4.3-A	Format Used for Drug Product Launch	4-18
4.3-B	Investigation of New Delivery Technologies	4-20
4.3-C	Needle-Based versus Needle-Free Delivery Technologies Under Investigation	4-21

# Biopharmaceutical Contract Fill-and-Finish: Best Practices Study 2015

## LIST OF FIGURES (continued)

---

### Chapter 4

4.3-D	Respondents' Special Handling Requirements	4-23
4.3-E	Distribution of Percent of Products with Special Handling Needs	4-24
4.3-F	Special Handling Needs Required	4-25
4.3-G	Handling Needs for Typical Biologics	4-25
4.3-H	Distribution of Average Fill-and-Finish Yield Losses	4-28
4.4-A	Distribution of Respondents with In-House Capacity	4-32
4.4-B	Changes to In-House Filling Capacity	4-38
4.4-C	Core Technology's Impact on Outsourcing Decisions	4-41
4.4-D	Standard Technology's Impact on Outsourcing Decisions	4-46
4.6-A	Number '1' Ranked Good Service Characteristics	4-65
4.6-B	Most Important Good Service Characteristics by Weighted Ranking	4-67
4.6-C	Changing Opinion about Emerging-Market CMOs	4-79
4.7-A	Different Price Model Used for Commercial Products	4-85
4.7-B	Average Technology Transfer Fees Paid by Respondent Type	4-89
4.7-C	Payment of Reservation Fee	4-93
4.7-D	When Cancellation Charges are First Expected to be Incurred	4-96
4.7-E	Cancellation Fees: Average Percentages of the Total Contract Fee	4-97
4.8-A	Average Per-Batch Price by Clinical Phase	4-102
4.8-B	Unit Price versus Batch Size: Non-Lyophilization	4-102
4.8-C	Unit Price versus Batch Size: Lyophilization	4-103
4.8-D	Price per Batch by SafeBridge® Level: Vials	4-104
4.8-E	Price per Batch by SafeBridge® Level: Prefilled Syringes	4-104
4.8-F	Average Fill-and-Finish Outsourcing Budgets by Respondent Type	4-108
4.8-G	Simple Average: Percentage of F&F Outsourcing Budget by Service: 2015	4-110
4.8-H	Weighted Average: Percentage of F&F Outsourcing Budget by Service 2015	4-112
4.9-A	Search Modes for Fill-and-Finish CMOs	4-113
4.9-B	Warranties, Guarantees and Indemnifications	4-122
4.9-C	Negotiation of Contractor's Final Product Quality and Consequential Damages	4-123
4.9-D	Preference for Production Networks or Alliances	4-124
4.9-E	Preferred Characteristics of Production Networks or Alliances	4-125

### Chapter 5

5.1-A	Number of Years Fill-and-Finish Services Offered	5-2
5.1-B	One-Stop-Shop CMO Model	5-5
5.2-A	Dosage Forms Produced by Percent of Contractors Respondents	5-8
5.2-B	Percent of Fill Lines Available among Contractor Respondents for Various Dosage Forms	5-9
5.2-C	Comparison of Percent of Dosage Forms Produced by Contractor Type	5-10
5.2-D	Capacity Expansion Plans	5-15
5.2-E	Dosage Forms Being Added	5-16

# Biopharmaceutical Contract Fill-and-Finish: Best Practices Study 2015

## LIST OF FIGURES (continued)

---

### Chapter 5

5.3-A	Percent of Contracting Business by Product Type: 2015 and 2017	5-18
5.3-B	Fill Line Capacity Utilization Rate	5-20
5.3-C	Lyophilization Capacity Utilization Rates	5-21
5.3-D	Average Number of Employees by Function	5-25
5.3-E	Plans to Reduce Fill-and-Finish Manufacturing Costs	5-26
5.4-A	Average Yield Loss	5-31
5.5-A	Pricing Methods	5-35
5.5-B	Use of Different Pricing Methods Based on Product Phase	5-36
5.5-C	Dosage Form	5-39
5.5-D	Batch Size	5-39
5.5-E	Batch Pricing	5-40
5.5-F	Technology Transfer Fee Charged	5-41
5.5-G	Reservation Fee Charged	5-43
5.5-H	When Cancellation Fees Are First Charged	5-44
5.5-I	Average Targeted and Achieved Gross Profit Margins	5-47
5.6-A	Warranties, Guarantees and Indemnifications Accepted by F&F CMOs	5-55
5.6-B	Comparison of CMO and Pharma Respondents “Always” Negotiation Term	5-56
5.6-C	Plans for Production Network or Alliances with Clients	5-57
5.7-A	Average Annual Growth Rates: Industry Estimate versus Company Forecast	5-65
5.7-B	Service Revenue by Contractor Type: 2015	5-67
5.7-C	Revenue Contribution from Customer Groups by Contractor Type	5-69
5.7-D	Percentage of Business from the World Regions by Contractor Type	5-71